Actions of Levofloxacin 0.5.% Ohara in details
Pharmacology: Mechanism of Action: The main mechanism of action of Levofloxacin 0.5.% Ohara is the inhibition of DNA gyrase. It is 2-fold stronger than that of ofloxacin. There is not much difference between the minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC). The activity of Levofloxacin 0.5.% Ohara is bactericidal. In the observation of bacterial morphology, bacteriolysis can be seen in the concentration around MIC.
Orally administered Levofloxacin 0.5.% Ohara is rapidly and almost completely absorbed with peak plasma concentrations being obtained within 1 hr. The absolute bioavailability is approximately 100%. Food has little effect on the absorption of Levofloxacin 0.5.% Ohara.
Distribution in Plasma: Approximately 30-40% of Levofloxacin 0.5.% Ohara is bound to serum protein. Multiple dosing with Levofloxacin 0.5.% Ohara 500 mg once daily showed neglible accumulation. There is modest but predictable accumulation of Levofloxacin 0.5.% Ohara after doses of 500 mg twice daily. Steady state is achieved within 3 days.
Penetration into Tissues and Body Fluids: Penetration into Bronchial Mucosa, Epithelial Lining Fluid (ELF): Maximum Levofloxacin 0.5.% Ohara concentrations in bronchial mucosa and ELF were 8.3 mcg/mL and 10.8 mcg/mL, respectively. These were reached approximately 1 hr after administration.
Penetration into Lung Tissue: Maximum Levofloxacin 0.5.% Ohara concentrations in lung tissues were approximately 11.3 mcg/mL and were reached between 4-6 hrs after administration.
Metabolism: Levofloxacin 0.5.% Ohara is metabolised to a very small extent, the metabolites being desmethyl-levofloxacin and Levofloxacin 0.5.% Ohara N-oxide. These metabolites account for <5% of the dose excretion in urine. Levofloxacin 0.5.% Ohara is stereochemically stable and does not undergo chiral inversion.
Elimination: Following oral and IV administration, Levofloxacin 0.5.% Ohara is eliminated relatively slowly from the plasma (half-life: 6-8 hrs). Excretion is primarily by the renal route (>85% of the administered dose).
Microbiology: Levofloxacin 0.5.% Ohara is a broad-spectrum antibacterial agent against gram-positive and gram-negative bacteria including anaerobes. Levofloxacin 0.5.% Ohara has shown strong antibacterial activities against Staphylococcus spp, Streptococcus pneumoniae, Streptococcus pyogenes, Streptococcus hemolyticus, Enterobacter spp, Escherichia coli, Klebsiella spp, Serratia spp, Enterococcus spp, Proteus spp and other glucose nonfermentative gram-negative rods, Pseudomonas aeruginosa, Haemophilus influenzae and Neisseria gonorrhoeae. Morever, Levofloxacin 0.5.% Ohara has shown antibacterial activity against Chlamydia trachomatis. Levofloxacin 0.5.% Ohara has an excellent protective and treatment effects in mice.
How should I take Levofloxacin 0.5.% Ohara?
Take Levofloxacin 0.5.% Ohara only as directed by your doctor. Do not take more of it, do not take it more often, and do not take it for a longer time than your doctor ordered.
Levofloxacin 0.5.% Ohara comes with a Medication Guide. Read and follow the instructions carefully. Ask your doctor if you have any questions.
Levofloxacin 0.5.% Ohara oral liquid should be taken 1 hour before or 2 hours after eating. You may measure your dose with a marked measuring spoon, oral syringe, or medicine cup.
Levofloxacin 0.5.% Ohara tablets may be taken with meals or on an empty stomach.
Levofloxacin 0.5.% Ohara is best taken with a full glass (8 ounces) of water. Several additional glasses of water should be taken every day, unless otherwise directed by your doctor. Drinking extra water will help to prevent some unwanted effects of Levofloxacin 0.5.% Ohara.
Levofloxacin 0.5.% Ohara works best when there is a constant amount in the blood. To help keep the amount constant, do not miss any doses. Also, it is best to take the doses at evenly spaced times, day and night. For example, if you are to take one dose a day, try to take it at the same time each day.
If you need to take Levofloxacin 0.5.% Ohara for anthrax infection or plague, your doctor will want you to begin taking it as soon as possible after you are exposed to anthrax or bacteria causing the plague.
If you are taking aluminum or magnesium-containing antacids, iron supplements, multivitamins, didanosine (Videx®), sucralfate (Carafate®), or zinc, do not take them at the same time that you take Levofloxacin 0.5.% Ohara. It is best to take these medicines at least 2 hours before or 2 hours after taking Levofloxacin 0.5.% Ohara. These medicines may keep Levofloxacin 0.5.% Ohara from working properly.
Keep using Levofloxacin 0.5.% Ohara for the full treatment time, even if you feel better after the first few doses. Your infection may not clear up if you stop using the medicine too soon.
The dose of Levofloxacin 0.5.% Ohara will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of Levofloxacin 0.5.% Ohara. If your dose is different, do not change it unless your doctor tells you to do so.
The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.
- For oral dosage forms (oral solution or tablets):
- For treatment of an infection:
- Adults—250 to 750 milligrams (mg) once a day.
- Children—Use and dose must be determined by your doctor.
- For preventing anthrax infection:
- Adults—500 milligrams (mg) once a day.
- Children 6 months of age and older and weighing more than 50 kilograms (kg)—500 mg once a day.
- Children 6 months of age and older and weighing less than 50 kg—Dose is based on body weight and must be determined by your doctor. The dose is usually 8 mg per kg of body weight per dose, given two times a day. However, the dose is usually not more than 250 mg.
- Infants younger than 6 months of age—Use and dose must be determined by your doctor.
- For treatment and prevention of plague:
- Adults—500 milligrams (mg) once a day.
- Children 6 months of age and older, weighing more than 50 kilograms (kg)—500 mg once a day.
- Children 6 months of age and older, weighing less than 50 kg—Dose is based on body weight and must be determined by your doctor. The dose is usually 8 mg per kg of body weight per dose, given two times a day. However, the dose is usually not more than 250 mg.
- Infants younger than 6 months of age—Use and dose must be determined by your doctor.
- For treatment of an infection:
If you miss a dose of Levofloxacin 0.5.% Ohara, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.
Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.
Keep out of the reach of children.
Do not keep outdated medicine or medicine no longer needed.
Ask your healthcare professional how you should dispose of any medicine you do not use.
Levofloxacin 0.5.% Ohara administration
Oral soln: Should be taken on an empty stomach. Take on an empty stomach 1 hr before or 2 hr after meals. Ensure adequate fluid intake.
Tab: May be taken with or without food. Ensure adequate fluid intake.
Levofloxacin 0.5.% Ohara pharmacology
Mechanism of Action
Levofloxacin 0.5.% Ohara is a member of the fluoroquinolone class of antibacterial agents.
The mean ± SD pharmacokinetic parameters of Levofloxacin 0.5.% Ohara determined under single and steady-state conditions following oral tablet, oral solution, or intravenous (IV) doses of Levofloxacin 0.5.% Ohara are summarized in Table 8.
ND = not determined
Levofloxacin 0.5.% Ohara is rapidly and essentially completely absorbed after oral administration. Peak plasma concentrations are usually attained one to two hours after oral dosing. The absolute bioavailability of Levofloxacin 0.5.% Ohara from a 500 mg tablet and a 750 mg tablet of Levofloxacin 0.5.% Ohara are both approximately 99%, demonstrating complete oral absorption of Levofloxacin 0.5.% Ohara. Following a single intravenous dose of Levofloxacin 0.5.% Ohara to healthy volunteers, the mean ± SD peak plasma concentration attained was 6.2 ± 1.0 mcg/mL after a 500 mg dose infused over 60 minutes and 11.5 ± 4.0 mcg/mL after a 750 mg dose infused over 90 minutes. Levofloxacin 0.5.% Ohara
Oral Solution and Tablet formulations are bioequivalent.
Levofloxacin 0.5.% Ohara pharmacokinetics are linear and predictable after single and multiple oral or IV dosing regimens. Steady-state conditions are reached within 48 hours following a 500 mg or 750 mg once-daily dosage regimen. The mean ± SD peak and trough plasma concentrations attained following multiple once-daily oral dosage regimens were approximately 5.7 ± 1.4 and 0.5 ± 0.2 mcg/mL after the 500 mg doses, and 8.6 ± 1.9 and 1.1 ± 0.4 mcg/mL after the 750 mg doses, respectively. The mean ± SD peak and trough plasma concentrations attained following multiple once-daily IV regimens were approximately 6.4 ± 0.8 and 0.6 ± 0.2 mcg/mL after the 500 mg doses, and 12.1 ± 4.1 and 1.3 ± 0.71 mcg/mL after the 750 mg doses, respectively.
Oral administration of a 500 mg dose of Levofloxacin 0.5.% Ohara with food prolongs the time to peak concentration by approximately 1 hour and decreases the peak concentration by approximately 14% following tablet and approximately 25% following oral solution administration. Therefore, Levofloxacin 0.5.% Ohara Tablets can be administered without regard to food. It is recommended that Levofloxacin 0.5.% Ohara
Oral Solution be taken 1 hour before or 2 hours after eating.
The plasma concentration profile of Levofloxacin 0.5.% Ohara after IV administration is similar and comparable in extent of exposure (AUC) to that observed for Levofloxacin 0.5.% Ohara Tablets when equal doses (mg/mg) are administered. Therefore, the oral and IV routes of administration can be considered interchangeable.
Figure 2: Mean Levofloxacin 0.5.% Ohara Plasma Concentration vs. Time Profile: 750 mg
Figure 3: Mean Levofloxacin 0.5.% Ohara Plasma Concentration vs. Time Profile: 500 mg
The mean volume of distribution of Levofloxacin 0.5.% Ohara generally ranges from 74 to 112 L after single and multiple 500 mg or 750 mg doses, indicating widespread distribution into body tissues. Levofloxacin 0.5.% Ohara reaches its peak levels in skin tissues and in blister fluid of healthy subjects at approximately 3 hours after dosing. The skin tissue biopsy to plasma AUC ratio is approximately 2 and the blister fluid to plasma AUC ratio is approximately 1 following multiple once-daily oral administration of 750 mg and 500 mg doses of Levofloxacin 0.5.% Ohara respectively, to healthy subjects. Levofloxacin 0.5.% Ohara also penetrates well into lung tissues. Lung tissue concentrations were generally 2- to 5-fold higher than plasma concentrations and ranged from approximately 2.4 to 11.3 mcg/g over a 24-hour period after a single 500 mg oral dose.
In vitro, over a clinically relevant range (1 to 10 mcg/mL) of serum/plasma Levofloxacin 0.5.% Ohara concentrations, Levofloxacin 0.5.% Ohara is approximately 24 to 38% bound to serum proteins across all species studied, as determined by the equilibrium dialysis method. Levofloxacin 0.5.% Ohara is mainly bound to serum albumin in humans. Levofloxacin 0.5.% Ohara binding to serum proteins is independent of the drug concentration.
Levofloxacin 0.5.% Ohara is stereochemically stable in plasma and urine and does not invert metabolically to its enantiomer, D-ofloxacin. Levofloxacin 0.5.% Ohara undergoes limited metabolism in humans and is primarily excreted as unchanged drug in the urine. Following oral administration, approximately 87% of an administered dose was recovered as unchanged drug in urine within 48 hours, whereas less than 4% of the dose was recovered in feces in 72 hours. Less than 5% of an administered dose was recovered in the urine as the desmethyl and N-oxide metabolites, the only metabolites identified in humans. These metabolites have little relevant pharmacological activity.
Levofloxacin 0.5.% Ohara is excreted largely as unchanged drug in the urine. The mean terminal plasma elimination half-life of Levofloxacin 0.5.% Ohara ranges from approximately 6 to 8 hours following single or multiple doses of Levofloxacin 0.5.% Ohara given orally or intravenously. The mean apparent total body clearance and renal clearance range from approximately 144 to 226 mL/min and 96 to 142 mL/min, respectively. Renal clearance in excess of the glomerular filtration rate suggests that tubular secretion of Levofloxacin 0.5.% Ohara occurs in addition to its glomerular filtration. Concomitant administration of either cimetidine or probenecid results in approximately 24% and 35% reduction in the Levofloxacin 0.5.% Ohara renal clearance, respectively, indicating that secretion of Levofloxacin 0.5.% Ohara occurs in the renal proximal tubule. No Levofloxacin 0.5.% Ohara crystals were found in any of the urine samples freshly collected from subjects receiving Levofloxacin 0.5.% Ohara.
There are no significant differences in Levofloxacin 0.5.% Ohara pharmacokinetics between young and elderly subjects when the subjects' differences in creatinine clearance are taken into consideration. Following a 500 mg oral dose of Levofloxacin 0.5.% Ohara to healthy elderly subjects (66 – 80 years of age), the mean terminal plasma elimination half-life of Levofloxacin 0.5.% Ohara was about 7.6 hours, as compared to approximately 6 hours in younger adults. The difference was attributable to the variation in renal function status of the subjects and was not believed to be clinically significant. Drug absorption appears to be unaffected by age. Levofloxacin 0.5.% Ohara dose adjustment based on age alone is not necessary.
The pharmacokinetics of Levofloxacin 0.5.% Ohara following a single 7 mg/kg intravenous dose were investigated in pediatric patients ranging in age from 6 months to 16 years. Pediatric patients cleared Levofloxacin 0.5.% Ohara faster than adult patients, resulting in lower plasma exposures than adults for a given mg/kg dose. Subsequent pharmacokinetic analyses predicted that a dosage regimen of 8 mg/kg every 12 hours (not to exceed 250 mg per dose) for pediatric patients 6 months to 17 years of age would achieve comparable steady state plasma exposures (AUC0-24 and Cmax) to those observed in adult patients administered 500 mg of Levofloxacin 0.5.% Ohara once every 24 hours.
There are no significant differences in Levofloxacin 0.5.% Ohara pharmacokinetics between male and female subjects when subjects' differences in creatinine clearance are taken into consideration. Following a 500 mg oral dose of Levofloxacin 0.5.% Ohara to healthy male subjects, the mean terminal plasma elimination half-life of Levofloxacin 0.5.% Ohara was about 7.5 hours, as compared to approximately 6.1 hours in female subjects. This difference was attributable to the variation in renal function status of the male and female subjects and was not believed to be clinically significant. Drug absorption appears to be unaffected by the gender of the subjects. Dose adjustment based on gender alone is not necessary.
The effect of race on Levofloxacin 0.5.% Ohara pharmacokinetics was examined through a covariate analysis performed on data from 72 subjects: 48 white and 24 non-white. The apparent total body clearance and apparent volume of distribution were not affected by the race of the subjects.
Clearance of Levofloxacin 0.5.% Ohara is substantially reduced and plasma elimination half-life is substantially prolonged in adult patients with impaired renal function (creatinine clearance < 50 mL/min), requiring dosage adjustment in such patients to avoid accumulation. Neither hemodialysis nor continuous ambulatory peritoneal dialysis (CAPD) is effective in removal of Levofloxacin 0.5.% Ohara from the body, indicating that supplemental doses of Levofloxacin 0.5.% Ohara are not required following hemodialysis or CAPD.
Pharmacokinetic studies in hepatically impaired patients have not been conducted. Due to the limited extent of Levofloxacin 0.5.% Ohara metabolism, the pharmacokinetics of Levofloxacin 0.5.% Ohara are not expected to be affected by hepatic impairment.
The pharmacokinetics of Levofloxacin 0.5.% Ohara in patients with serious community-acquired bacterial infections are comparable to those observed in healthy subjects.
The potential for pharmacokinetic drug interactions between Levofloxacin 0.5.% Ohara and antacids warfarin, theophylline, cyclosporine, digoxin, probenecid, and cimetidine has been evaluated.
Mechanism of Action
Levofloxacin 0.5.% Ohara is the L-isomer of the racemate, ofloxacin, a quinolone antimicrobial agent. The antibacterial activity of ofloxacin resides primarily in the L-isomer. The mechanism of action of Levofloxacin 0.5.% Ohara and other fluoroquinolone antimicrobials involves inhibition of bacterial topoisomerase IV and DNA gyrase (both of which are type II topoisomerases), enzymes required for DNA replication, transcription, repair and recombination.
Mechanism of Resistance
Fluoroquinolone resistance can arise through mutations in defined regions of DNA gyrase or topoisomerase IV, termed the Quinolone-Resistance Determining Regions (QRDRs), or through altered efflux.
Fluoroquinolones, including Levofloxacin 0.5.% Ohara, differ in chemical structure and mode of action from aminoglycosides, macrolides and ß-lactam antibiotics, including penicillins. Fluoroquinolones may, therefore, be active against bacteria resistant to these antimicrobials.
Resistance to Levofloxacin 0.5.% Ohara due to spontaneous mutation in vitro is a rare occurrence (range: 10-9 to 10-10). Cross-resistance has been observed between Levofloxacin 0.5.% Ohara and some other fluoroquinolones, some microorganisms resistant to other fluoroquinolones may be susceptible to Levofloxacin 0.5.% Ohara.
Activity in vitro and in vivo
Levofloxacin 0.5.% Ohara has in vitro activity against Gram-negative and Gram-positive bacteria.
Levofloxacin 0.5.% Ohara has been shown to be active against most isolates of the following bacteria both in vitro and in clinical infections as described in :
Staphylococcus aureus (methicillin-susceptible isolates)
Staphylococcus epidermidis (methicillin-susceptible isolates)
Streptococcus pneumoniae (including multi-drug resistant isolates [MDRSP])1
1 MDRSP (Multi-drug resistant Streptococcus pneumoniae) isolates are isolates resistant to two or more of the following antibiotics: penicillin (MIC ≥ 2 mcg/mL), 2nd generation cephalosporins, e.g., cefuroxime; macrolides, tetracyclines and trimethoprim/sulfamethoxazole.
The following in vitro data are available, but their clinical significance is unknown: Levofloxacin 0.5.% Ohara exhibits in vitro minimum inhibitory concentrations (MIC values) of 2 mcg/mL or less against most (≥ 90%) isolates of the following microorganisms; however, the safety and effectiveness of Levofloxacin 0.5.% Ohara in treating clinical infections due to these bacteria have not been established in adequate and well-controlled clinical trials.
ß-hemolytic Streptococcus (Group C/F)
ß-hemolytic Streptococcus (Group G)
Viridans group streptococci
Anaerobic Gram-Positive Bacteria
When available, the clinical microbiology laboratory should provide the results of in vitro susceptibility test results for antimicrobial drug products used in the resident hospitals to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens. These reports should aid the physician in selecting an antibacterial drug product for treatment.
Quantitative methods are used to determine antimicrobial minimal inhibitory concentrations (MICs). These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds. The MIC values should be determined using a standardized procedure. Standardized procedures are based on a dilution method1, 2, 4 (broth or agar) or equivalent with standardized inoculum concentrations and standardized concentrations of Levofloxacin 0.5.% Ohara powder. The MIC values should be interpreted according to the criteria outlined in Table 9.
Quantitative methods that require measurement of zone diameters also provide reproducible estimates of the susceptibility of bacteria to antimicrobial compounds. One such standardized procedure2, 3 requires the use of standardized inoculum concentrations. This procedure uses paper disks impregnated with 5 mcg Levofloxacin 0.5.% Ohara to test the susceptibility of bacteria to Levofloxacin 0.5.% Ohara.
Reports from the laboratory providing results of the standard single-disk susceptibility test with a 5 mcg Levofloxacin 0.5.% Ohara disk should be interpreted according to the criteria outlined in Table 9.
A report of Susceptible indicates that the pathogen is likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable. A report of Intermediate indicates that the result should be considered equivocal, and, if the microorganism is not fully susceptible to alternative, clinically feasible drugs, the test should be repeated. This category implies possible clinical applicability in body sites where the drug is physiologically concentrated or in situations where a high dosage of drug can be used. This category also provides a buffer zone which prevents small uncontrolled technical factors from causing major discrepancies in interpretation. A report of Resistant indicates that the pathogen is not likely to be inhibited if the antimicrobial compound in the blood reaches the concentrations usually achievable; other therapy should be selected.
Standardized susceptibility test procedures require the use of laboratory controls to monitor and ensure the accuracy and precision of supplies and reagents used in the assay, and the techniques of the individuals performing the test.1,2,3,4 Standard Levofloxacin 0.5.% Ohara powder should provide the range of MIC values noted in Table 10. For the diffusion technique using the 5 mcg disk, the criteria in Table 10 should be achieved.
- EPA DSStox. "Levofloxacin: DSSTox provides a high quality public chemistry resource for supporting improved predictive toxicology.". https://comptox.epa.gov/dashboard/dsstox... (accessed September 18, 2017).
- NCIt. "Levofloxacin: NCI Thesaurus (NCIt) provides reference terminology for many systems. It covers vocabulary for clinical care, translational and basic research, and public information and administrative activities.". https://ncit.nci.nih.gov/ncitbrowser/Con... (accessed September 18, 2017).
ReviewsThe results of a survey conducted on ndrugs.com for Levofloxacin 0.5.% Ohara are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Levofloxacin 0.5.% Ohara. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.
Information checked by Dr. Sachin Kumar, MD Pharmacology